https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / Int J Hyperthermia 2020 07;37(2):3-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / Int J Hyperthermia 2020 07;37(2):3-192020-07-01 00:00:002020-07-01 00:00:00Hyperthermia treatment advances for brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / J Immunother Cancer 2020 07;8(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / J Immunother Cancer 2020 07;8(2)2020-07-01 00:00:002021-05-12 07:32:39Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / J Thorac Oncol 2020 Jul;15(7):e111-e113
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / J Thorac Oncol 2020 Jul;15(7):e111-e1132020-07-01 00:00:002020-07-01 00:00:00Oncolytic Viral Therapy for Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-6462020-06-30 00:00:002021-11-15 13:19:48Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-30 / Crit. Rev. Biotechnol. 2020 Sep;40(6):804-820
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-30 / Crit. Rev. Biotechnol. 2020 Sep;40(6):804-8202020-06-30 00:00:002020-06-30 00:00:00State-of-the-art exosome loading and functionalization techniques for enhanced therapeutics: a review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-29 / Cancer Cell Int. 2020;20:278
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-29 / Cancer Cell Int. 2020;20:2782020-06-29 00:00:002020-06-29 00:00:00Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-27 / Virusdisease 2020 Sep;31(3):341-348
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-27 / Virusdisease 2020 Sep;31(3):341-3482020-06-27 00:00:002020-06-27 00:00:00Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-3032020-06-24 00:00:002021-05-12 07:29:51CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-21 / J Control Release 2020 Jun;326:63-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-21 / J Control Release 2020 Jun;326:63-742020-06-21 00:00:002020-06-21 00:00:00Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-15 / Nanomedicine 2020 Jun;29:102240
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-15 / Nanomedicine 2020 Jun;29:1022402020-06-15 00:00:002020-06-15 00:00:00Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy
